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Abstract
Cerebral microdialysis (CMD) is used in severe traumatic brain injury (TBI) in order to recover 
metabolites in brain extracellular fluid (ECF). To recover larger proteins and avoid fluid loss, 
albumin supplemented perfusion fluid (PF) has been utilised, but due to regulatory changes in the 
EU, this is no long r practicable. The aim with this study was to see if fluid-, absolute- (AR) - 
and relative (RR) recovery for the novel carrier Dextran 500 was better than conventional PF, for 
a range of cytokines and chemokines and if the recovery was affected by molecular weight (MW) 
and isoelectric-point. An in vitro set-up mimicking conditions seen in the neurocritical care of 
TBI patients was used, utilizing 100 kDa MW cut-off CMD catheters inserted through a triple-
lumen bolt cranial access device into an external solution with diluted cytokine standards in 
known concentrations for 48 hours (divided into 6-hours epochs). Samples were run on a 39-
plex-Luminex assay to assess cytokine concentrations. We found that fluid recovery was 
inadequate in 50% of epochs with conventional PF, while Dextran PF overcame this limitation. 
The AR was higher in the Dextran PF samples for a majority of cytokines, and RR was 
significantly increased for six cytokines (eotaxin, IL-6, M-CSF, CCL3, RANTES and TGF-
alpha). In summary, Dextran PF improved fluid and cytokine recovery as compared to 
conventional PF and is a suitable alternative to albumin supplemented PF for protein 
microdialysis.
Keywords: Microdialysis; in vitro; recovery; cytokines; chemokines; Dextran 500
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Introduction
Cerebral microdialysis (CMD) is a technique enabling sampling from the extracellular fluid (ECF) 
in vivo, providing a unique opportunity to study underlying metabolic and inflammatory processes 
that occur in TBI.1, 2 Microdialysis sampling is based on the free diffusion of analytes across a 
semi-permeable m mbrane with a nominal molecular weight cut-off (MWCO). The membrane is 
attached to inlet and outlet tubing through which perfusion fluid (PF) is slowly pumped and 
collected.3 To measure metabolites in clinical practice, such as glucose, lactate and pyruvate, a 
20kDa MWCO is adequate and an isotonic solution, mimicking cerebrospinal fluid (CSF), is used 
as carrier.4 Microdialysis of proteins is limited by both lower absolute concentrations within the 
brain ECF, as well as the larger molecular weight, necessitating the use of larger MWCO 
membranes. This causes a number of problems, including non-specific adsorption to the device 
materials, clogging of membranes and protein-protein interactions which all negatively affect 
recovery.5-7 A further issue with increased MWCO catheters (e.g. 100 kDa), is loss by convection 
of fluid within the catheter.8 This is due to the hydrostatic pressure differences (with a relatively 
low osmotic pressure in the PF) and referred to as ultrafiltration. This may impact on both the 
ability to carry out analysis on the diminished volume of fluid recovered by the catheter as well as 
potentially impacting on the biology of the extracellular space, such that it is not representative of 
the underlying processes of interest. In order to mitigate this phenomenon, addition of colloid to 
the PF to increase the oncotic pressure has been recommended, typically albumin.6, 9 However, a 
regulatory reclassification of albumin within the EU as a blood product has made formulation of 
albumin supplemented fluid logistically and financially impractical. Furthermore, the theoretical 
risk of albumin leak and accumulation in the surrounding tissues has been raised, with potential 
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negative consequences.8 Our group and others have shown that cytokines and chemokines are key 
mediators in the inflammatory processes following TBI, 10-12 and in order to advance the study of 
brain protein recovery and potential therapeutic advances, an accurate estimation of relative 
recovery is necessary. Thus, it is imperative for the continued clinical use of microdialysis that 
alternative strategies for improving cytokine recovery which do not require blood products are 
developed and tested.
An alternative colloid to increase the osmotic- and hydrostatic pressure of microdialysis PF is 
Dextran.13-15 Dextrans are branched glycans of varying molecular sizes (3 – 2,000 kDa), of which 
ranges between 60 to 500 kDa have been extensively studied in the microdialysis setting.7, 9, 16, 17 
In comparison to normal PF, and even albumin PF, studies have shown an improved recovery of 
macromolecules using different molecular weights and concentrations of Dextrans.7, 9, 16 Recent in 
vitro studies have suggested that a 3% Dextran 500 kDa solution is the most suitable additive as it 
is large enough not to pass through the microdialysis membrane,18 maintains the greatest fluid 
recovery7, 14 and does not lead to an inflammatory response in the surrounding tissue.8 
Thus, the aim of this study was to determine whether PF supplemented with the recently 
commercially available 3 % Dextran 500 kDa (Perfusion Fluid CNS Dextran, M Dialysis, 
Stockholm, Sweden) could improve the fluid-, absolute- (AR)- and relative recovery (AR and RR) 
of inflammatory markers (39 cytokines and chemokines) during microdialysis sampling in vitro, 
in comparison to normal PF available for clinical use (Perfusion Fluid CNS, M Dialysis, 
Stockholm, Sweden). The two types of PF were tested using an in vitro set-up that closely 
approximates the clinical environment, to ascertain whether Dextran would be worthwhile to use 
during microdialysis sampling in human patients. 
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Material and Methods
Materials
All high-purity deionised water (dH2O) used was of HPLC-grade (18.2 MΩ.cm, Millipore Direct 
Q5 UV water purification system with LC-Pak polisher). All reagents were also of analytical 
grade, purchased from Sigma-Aldrich (Poole, Dorset, UK) and used as received unless otherwise 
stated. Sodium chloride and potassium chloride were purchased from BDH Laboratory Supplies 
(Poole, UK). 
M Dialysis 71 CMD catheters (100 kDa nominal MWCO, polyarylethersulfone [PAES] 10 mm 
membrane length), microdialysis vials, Perfusion Fluid CNS, Perfusion Fluid CNS Dextran, M 
Dialysis 106 microdialysis pumps and corresponding batteries and syringes were purchased from 
M Dialysis (Stockholm, Sweden). Both PFs contain 147 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2, 
0.85 mM MgCl2 but with an additional 3% 500 kDa molecular weight Dextran in the Perfusion 
Fluid CNS Dextran. This newly commercially available product was purchased from M Dialysis 
(Stockholm, Sweden).
In vitro microdialysis sampling experiments were performed using a VWR advanced hotplate 
magnetic stirrer with temperature probe. Catheters were held in place during in vitro sampling 
using a triple lumen cranial access device (Technicam, Newton Abbott, UK). Custom Invitrogen 
eBioscience ProcartaPlexTM human cytokine and chemokine 39-plex bead assays, and human 
cytokine and chemokine standards (referred to by the manufacturer as “A”, “B”, “C”, “D”, “E”, 
“G”, “K”, “L”, and “MMP” standard mixes, plus individual standards for Galectin-3, MDC, and 
TGF alpha) were purchased from Thermo Fisher (Paisley, UK). A complete list of the cytokines 
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and chemokines analysed is provided in Supplementary Table 1. ProcartaPlex multiplex assays 
were analysed using a Luminex 200 analyser (Luminex Corporation, Austin TX, USA) operating 
with Luminex xPONENT® software. Wash steps were performed using a ProcartaPlex handheld 
magnetic plate holder.   
In vitro microdialysis sampling
In vitro microdialysis sampling was performed using an artificial external solution (ES) 
representative of the brain extracellular environment. The ES comprised PF with 0.05 % (w/v) 
sodium azide, 1 mg/mL HSA, and 39 human cytokines and chemokines, prepared in a 50 mL 
centrifuge tube (Falcon) as follows. Microdialysis perfusion fluid (PF) for the external solution 
was made in-house (147 mM NaCl, 2.7 mM KCl, 1.2 mM CaCl2, 0.85 mM MgCl2; pH ~ 6.0), to 
the same specifications as Perfusion Fluid CNS used for CMD in patients. The mixed cytokine 
and chemokine standards (A, B, C, D, E, G, K, L, and MMP standard mixes, plus individual 
standards for Galectin-3, MDC, and TGF-alpha), received as lyophilised powders, were 
resuspended in accordance with the manufacturers’ instructions and subsequently diluted to 1:100 
in PF with 0.05 % (w/v) sodium azide and 1 mg/mL HAS (final concentration). The total volume 
of the ES was 25 mL. The final cytokine and chemokine concentrations are shown in 
Supplementary Table 1.
The centrifuge tube (50 mL) containing the ES (25 mL) was suspended using a clamp stand in a 
thermostatically controlled glycerol bath (to avoid condensation) set to 37 °C. Very gentle 
agitation of the external solution was applied using a magnetic stirrer. Two M Dialysis 71 brain 
microdialysis catheters were placed into the external solution through a triple bolt cranial access 
device, which was secured within the centrifuge tube using self-adhesive plastic film. Each 
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catheter was perfused at 0.3 µL/min using M Dialysis 107 pumps, with syringes loaded with ca. 
1.5 mL of either normal PF, or PF containing 3 % Dextran 500. Both the normal PF and the 
Dextran PF were used as received from the manufacturer. The microdialysate samples were 
collected in microdialysis vials at the end of each catheter. Pumps and collection vials were kept 
at the same height either side of the glycerol bath, to nullify any hydrostatic pressure differences. 
Sampling was performed for 48 h in total; the microdialysis vials were changed every 6 h and 
sample from the ES was drawn at the 0h, 24h and 48h time-points every 24 and 48 hours. A 
schematic of the in vitro sampling set-up is shown in Fig 1. If no fluid was apparent in the 
microdialysis vial during the first 30-60 minutes following an exchange, that pump was flushed. 
This flush sequence was discarded and fluid collection started after the flush was completed. The 
pumps were randomly changed between fluid carriers and experiments as to not introduce any 
systematic bias. The in vitro sampling test was repeated in 3 independent experiments over the 
course of 4 weeks (8 time-epochs per experiments, a total of 24 epochs). All samples were stored 
at -80 °C prior to analysis.
Sample analysis
Quantitative analysis of cytokine and chemokines was performed using custom ProcartaPlexTM 
human 39-plex bead-based immunoassay kits. The samples were thawed and gently mixed before 
analysing. In total, 25 µL of sample was used per well; all samples were analysed in duplicate. 
The assay was performed as per the manufacturers’ instructions. Wash steps were carried out 
using a handheld magnetic plate holder (ProcartaPlex). All assays were analysed on a Luminex 
200 platform. We established that Dextran 500 did not interfere with the analysis by running a 
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standard curve using the Dextran PF as a diluent and compared it to a normal PF standard curve, 
and Dextran PF had no discernible effect on the standard response. 
Statistical analysis
All statistical analyses were conducted using the statistical software R, and its graphical interface 
Rstudio®.19 For each described analysis below, complete case analyses were conducted. A p-
value  0.05 was considered significant in all analyses. Graphical presentation was conducted 
using the R-packages tidyverse,20 cowplot,21 and RColorBrewer22 unless otherwise stated. 
To assess how flushing the pumps affected cytokine recovery in the remaining fluid collected in 
that epoch, we used the R-package nlme23 and conducted a linear mixed model per cytokine, 
using cytokine recovery as dependent variable and time together with flush as independent 
variables.24 In each model, the independent experiment was considered to be the random 
intercept. Some cytokines (Fractalkine, IFN-, IF -, TNF-RI) could not be quantified in the 
microdialysates, as the concentrations recovered were below the lower limit of detection (as 
specified by the kit manufacturer) for the assay. Assumptions were examined graphically with 
regards to equal variance, linearity, and normal distribution. 
Similarly, for absolute recovery analysis, time and carrier were used as independent variables in a 
mixed model.23-26 The dependent variable was the recovered cytokine value. For random 
intercepts, we used independent experiments. IFN- was excluded from analysis since the 
returned levels were below lowest levels of detection for both PFs. Assumptions were examined 
graphically as described above.27, 28  
Relative recovery (RR) was calculated as the ratio between the recovered cytokine in the 
microdialysis carriervial (numerator) and the recovered cytokine in the ES (denominator) 
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obtained concomitantly at 24- and 48-hours. For inferential analysis, cytokines exhibiting < 3 
positive observations (CCL20/MIP-3-, Fractalkine, Galectin-3, IFN-, IFN-, MMP-2, TNF-RI, 
VEGF-D) were excluded. For the remainders, the cytokine retrieval capacity of the different 
carriers (Dextran and the conventional CNS PF) were compared using a two-sided Student’s T-
test (not assuming equal variances) or (if not normally distributed) a two-sided Mann Whitney U 
test. 
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Results
Fluid recovery
Only vials perfused with the standard PF demonstrated inadequate fluid recovery in certain 
epochs over the three experiments, and hence needed intermittent flushing in the initial phase of 
the epoch (Fig 2). In total, 50% of the vials (12 epochs) needed flushing (Fig 2A). In these cases, 
sampling was briefly halted while the flush sequence was completed, and resumed immediately 
afterward. The eluent from the flush sequence was collected separately from the sample fluid and 
discarded in order to avoid diluting the samples with excess fluid. For most cytokines, this 
procedure did not alter the absolute recovery (Table 1), but for some, notably IL-6, RANTES and 
TNF, the necessary flushing sequences resulted in a significantly lower recovery in the fluid 
collected during the remaining of the epoch in the conventional CNS PF (Fig 2A).
Absolute recovery 
Throughout the analysed cytokines, the absolute recovery was systematically higher for the 
Dextran CNS PF carrier compared to the standard CNS PF (Table 1). Two examples are 
highlighted in Fig 3. The samples using Dextran as carrier also had more robust results overall, as 
visualized by Supplementary Fig 1. Further, many protein concentrations varied over time, 
usually with a decreasing trajectory, presumably representing a spontaneous gradual decline of 
some of the proteins in the study (Table 1), presumably due to processes such as decomposition, 
aggregation, and/or adhesion to surfaces etc.  
Relative recovery
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At 24 and 48 hours, the ES was sampled to enable calculation of the RR, generating a maximum 
of 6 RRs per cytokine (2 per individual experiment). Overall, there was a general trend towards a 
higher RR for the Dextran perfusion fluid as compared to the standard CNS (Table 1) (Fig 4). 
Two cytokines exhibited a significant increase in RR with Dextran PF, including M-CSF and 
TGF-alpha, while none of the cytokines’ RR values were significantly higher in the standard 
CNS perfusion fluid. 
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Discussion
To our knowledge, this is the first study using the CE-marked commercially available Perfusion 
Fluid CNS Dextran 500 from µDialysis, applicable for human use. This work represents a 
comprehensive overview of in vitro cytokine/chemokine recovery using this new fluid carrier as 
compared to the conventional Perfusion Fluid CNS. We found that the fluid- and absolute 
recovery were much more robust when the Dextran was used in the carrier fluid. Two cytokines 
also had a significantly higher RR when Dextran was used in the carrier fluid, suggesting it to be 
a preferable PF in comparison to conventional CNS PF. 
Dextran resulted in an improved fluid recovery
The catheters perfused with normal CNS PF needed to be “flushed” in 50% of the epochs to 
reach expected adequate sample volumes, as compared to the Dextran PF which always reached 
sufficient volumes of recovery in the collection vials. This is presumably due to ultrafiltration 
causing a fluid loss over the membrane of CNS PF due to low osmotic pressure,9 though other 
explanations, such as varying catheter capabilities depending on the surrounding medium (in vivo 
vs in vitro), have also been suggested.6 Similarly, in an in vitro recovery study by Dahlin and co-
workers, they noticed a 30% fluid recovery decrease in CNS PF compared to an in-house Dextran 
500 solution and only if special surface coated catheters were used (otherwise they did not see 
any recovery at all),7 similar to Kahl et al. using Ringer’s solution as PF.16 Our 50% is similar to 
the previous study from our group comparing 3.5% albumin with normal CNS PF which revealed 
that 44% of CNS PF epochs had inadequate fluid recovery compared to none using the albumin 
colloid.6 There have been no comparisons between Dextran 500 and 3.5% albumin PF, but a 
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study from 2005 analyzed Dextran 60 and saw that the fluid recovery was slightly better for 
albumin, but this difference was insignificant as both fluid recoveries were almost 100%.9 It 
should be noted that the lower fluid volumes we noticed is not as evident for catheters with 
normal CNS PF placed in brain ECF in vivo, presumably due to different pressure gradients and 
other factors such as endogenous proteins,6, 14 but a phenomenon more commonly seen in in vitro 
studies.6, 29 That being said, we believe the robust fluid recovery seen for Dextran PF is 
translatable to the clinical scenario akin to the benefit seen with 3.5% Albumin PF.6 In our 
experience, colloid supplemented PF mitigates against catheter failure during clinical use and 
reduces the need for catheter replacement. Overall, the Dextran 500 PF shows superior fluid 
recovery as compared to the normal CNS PF, most likely to due to the opposing oncotic pressure 
generated by the colloid within the microdialysis perfusate.
Dextran PF improved recovery of cytokine/chemokines
We found that overall, the Dextran PF was superior to normal CNS PF in recovery across a range 
of cytokines. Almost all cytokines had a significantly higher improved absolute recoveryAR, and 
the RRs in the current study was significantly higher for two of the proteins, namely M-CSF and 
TGF-alpha, using the Dextran PF, compared with CNS PF. While data on Dextran 500 PF from 
M Dialysis has never been published before in a similar fashion, Dahlin and co-workers in 
Uppsala, Sweden, have escalated Dextran concentrations, and molecular weight of Dextran 
molecules, and noted an improved recovery of some cytokines for Dextran 500 compared to CNS 
PF.7 However, their study was not structured in a similar fashion as ours making direct 
comparisons difficult, but researchers from Uppsala have now shifted to an in-house Dextran 500 
as a colloid in PF and successfully recovered larger proteins in swine and rat brain injury 
models.30, 31 
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Our group has previously performed similar in vitro analyses comparing a 3.5% albumin PF vs 
normal CNS PF,6 showing a RR improvement in the colloid in 9 out of 12 analyzed cytokines. 
Further, the RRs in that study reached 30-50%, often double that of CNS PF.6 These RRs were 
higher than those seen in the current study which revealed mean RRs of 1-10%, with some higher 
responders (e.g. TGF-alpha). We cannot easily explain this apparent disparity with our earlier 
studies, but this might be partly attributable to the different assay used and more extensive 
protein-protein interaction due to more proteins involved in the present study. In the present study 
we used continuous stirring of the external solution. Comparing with the literature, some in vitro 
recovery studies employed stirring, while some did not.6, 32, 33 It is conceivable that stirring may 
have an effect on recovery, as the surface chemistry of interaction with a solution is a potentially 
complex situation in which layers and gradients can form, potentially affected by stirring. 
However, these lower RRs seem to be more in line with some previously published studies,32, 34-37 
where RRs in the range of 1-10% are often seen, although with some reaching higher levels. This 
distinct heterogeneity in results – depending on different study set-ups – means that caution must 
be exercised when comparing absolute RR between different studies.
Previous studies have shown that catheters are susceptible to biofouling over time (or even being 
malformed), decreasing the RR.6, 38 We compared RRs at 24h vs 48h, and this was not evident in 
our dataset (data not shown), so even if protein depositions occurred they did not affect the 
recovery. Instead, a more probable explanation for the decrease in absolute recovery is that the 
ES concentrations decreased for many cytokines over time, which may be due to decay of the 
cytokines in the standard over 48 hours at 37oC (Supplementary Table 1). Decreases in RR with 
time, and in ES concentration with time, in a different in vitro microdialysis setup have 
previously also been reported, for IL-1alpha, IL-1beta and IL-1ra.12 
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Dextran 500 and 3.5% albumin have not been compared directly in a similar fashion. However, 
Khan and co-workers noted that albumin is preferable to hydroxyethyl starch (HES, similar to 
dextran) with superior recovery for some cytokines, while HES was better for others, tentatively 
prompting investigators to a choice of PF depending on which cytokine is to be analyzed.16
Future aspects and clinical implication for metabolite recovery
It is unknown what effect (if any) Dextran PF will have on the recovery of clinically analysed 
metabolites (e.g. glucose, lactate and pyruvate) as compared to normal CNS PF. A variant of 
Dextran 60 in PF was reportedly preferable to saline solutions in PF to recover glucose,13 and 
albumin in PF have been shown to have lower recovery of lactate compared to other colloids 
containing  different concentrations of HES.16 Therefore, dextran is presumably a preferable 
choice clinically as compared to albumin and normal CNS PF for the common metabolites, 
especially if 100 kDa catheters are used. However, before widespread clinical use, more 
extensive examinations of RR of normally monitored metabolites need to be performed.
Limitations
In the context of RR, the study was planned and designed for n=6 vs n=6 measurements. 
However, as many cytokines were not recovered in several epochs, many of these samples 
returned concentrations below lower limit of detection by the Luminex assay for this analyte. 
While it could be considered a limitation to compare fewer “positive” samples, these “zero” 
levels presumably represent important information as to highlight which cytokines and 
concentrations are suitable to recover using microdialysis in the current and similar scenarios. 
Furthermore, many of the recovered cytokines exhibited a higher variability than expected on the 
basis of our previous studies. We acknowledge that additional experimental runs would have 
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been desirable in the present study to increase the statistical sample sizes (n), as previously stated. 
Even so, the current results shed light on the individual cytokines’ different propensities for 
variability in recovery, and thus identify those cytokine species that behave most consistently 
with the current microdialysis technique.
We only compared the effect of the perfusion fluid in this study, whereas many other factors have 
been shown to alter MD recovery, including membrane lengths,13 membrane coating,31, 39 fluid 
pressure,14 inclusion of nano-particles,40 and MD-pump speed,7 which could be other ways to 
improve the recovery depending on the situation. We have specifically focused on the 
methodological constraints within clinical practice as a prelude to utilizing this perfusion fluid in 
clinical studies. As mentioned above, we checked that Dextran PF did not interfere with the 
Luminex assay. if different analytes are to be measured by other assay techniques, it would be 
important to perform tests to ascertain whether or not Dextran PF interferes with those assays. 
For example, preliminary tests we performed with ISCUSflex measurement of glucose, lactate 
and pyruvate suggested that Dextran 500 did not interfere with such measurements.
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Conclusions
In vitro studies are not fully representative of the situation in vivo, perhaps due to direct 
tissue/catheter interactions such that the outer boundary of the microdialysis catheter is in contact 
in vivo with cells, extracellular matrix and extracellular fluid in the brain tissue, rather than a 
simple in vitro fluid solution. This makes microdialysis measures such as FR and RR a 
necessarily crude estimate of the recovery of a given species in vivo. Nevertheless, the overall 
benefit of Dextran PF over conventional PF for the recovery of cytokines and chemokines is 
supported by these in vitro results and we therefore regard Dextran PF as showing promise as a 
perfusion fluid for use in clinical microdialysis studies requiring recovery of protein.
List of abbreviations
BAFF = B-cell activating factor, BDNF = Brain-derived neurotrophic factor, BLC = B 
Lymphocyte chemoattractant, CXCL13 = chemokine (C-X-C motif) ligand 13, CCL = CC 
chemokine ligands, G-CSF = Granulocyte colony-stimulating factor, GM-CSF = Granulocyte-
macrophage colony-stimulating factor, GRO = chemokine (C-X-C motif) ligand 1 (CXCL1), IFN 
= Interferon, IL = Interleukin, IL-1ra = Interleukin-1 receptor antagonist, IP-10/IP10 = Interferon 
gamma-induced protein 10 (also known as C-X-C motif chemokine 10 (CXCL10)), MCP-1 = 
Monocyte chemotactic protein 1 (also known as CCL2), MCP-3 = Monocyte chemotactic 
protein-3 (also known as CCL7), MDC = Macrophage-Derived Chemokine (also known as 
CCL22), MIP1α = Macrophage inflammatory protein 1 alpha (also known as CCL3), MIP1β =  
Macrophage inflammatory protein 1 beta (also known as CCL4), PDGF = Platelet-derived 
growth factor, RANTES = regulated on activation, normal T cell expressed and secreted (also 
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known as CCL5), sCD40L = soluble CD40 ligand, sIL-2Ra = Soluble Interleukin-2 receptor 
antagonist, TNF = Tumor necrosis factor, VEGF = Vascular Endothelial Growth Factor.
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Table 1. Recovery of different cytokines




How flush sequence 
during epoch influenced 
AR (mixed model) 
Relevance of MD pump 
flush (mixed model)




























































Fractalkine 0.006 <0.001 NA NA NA NA














IFN-alpha 0.059 0.142 NA NA NA NA
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CCL3/MIP-
1a

















MMP-2 0.150 <0.001 NA NA NA 0.200
MMP-9 0.386 0.258 NA NA NA 0.572































TNF-RI <0.001 0.001 NA NA NA NA





VEGF-D 0.195 0.854 NA NA NA 0.895
Table showing which cytokines that had an improved absolute recovery depending on carrier 
(Dextran PF or conventional PF) and which cytokines that significantly decreased over time. 
Mean relative recovery is shown for both the conventional PF and Dextran 500 PF, 
highlighting significant differences (Mann Whitney U Test). Cytokines with less than n=3 
detectable levels were noted as NA. Cytokines with insufficient recovered samples at 24 and 
48 hours could not be calculated (NA in the table). The influence that flushing the catheter 
system is included as well. Note that the flush eluate was not included in the actual sample 
for analysis. Sampling was briefly interrupted while the flush was performed (with flush 
eluate collected into a waste vial that was then discarded), and then sampling continued as 
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normal afterwards. Significant differences (p<0.05) are in bold. Abbreviations: AR – absolute 
recovery; RR – relative recovery; MD – Microdialysis; PF – Perfusion fluid; SEM – Standard 
error of the mean; NA – Not available.
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Figure 1 – Schematic overview of the experimental set-up. 
297x129mm (300 x 300 DPI) 
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Figure 2 – A time-chart of epochs needing MD pump flushing. 
Fig 2A shows the catheter perfused with Dextran 500 and Fig 2B conventional (CNS) perfusion fluid. Light 
blue indicates an adequate fluid recovery while dark blue highlights an epoch where a flushing sequence was 
necessary as we expected that an inadequate amount would be collected at the end of the epoch. 
254x114mm (300 x 300 DPI) 
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Figure 3 – Examples of absolute recovery over time.
Fig 3A shows an example of a cytokine were the recovery did not differ significantly over time and carrier 
(BAFF), while the recovery of eotaxin (Fig 3B) did change significantly over time or between the two 
carriers. Y-axis shows mean cytokine concentration (pg/ml) with standard error of mean as error bars and 
x-axis time (hours). 
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Figure 4 – Bar plot of all relative recoveries. 
Fig 4 shows the mean relative recoveries (error bars represent standard error of mean) from all 3 
independent experiments and pooled 24- and 48-hour time points. Y-axis displays the cytokines/chemokines 
while X-axis shows relative recovery. 
215x203mm (300 x 300 DPI) 
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Figure legends
Figure 1 – Schematic overview of the experimental set-up.
Figure 2 – A time-chart of epochs needing MD pump flushing. 
Fig 2A shows the catheter perfused with Dextran 500 and Fig 2B conventional (CNS) 
perfusion fluid. Light blue indicates an adequate fluid recovery while dark blue highlights an 
epoch where a flushing sequence was necessary as we expected that an inadequate amount 
would be collected at the end of the epoch.
Figure 3 – Examples of absolute recovery over time.
Fig 3A shows an example of a cytokine were the recovery did not differ significantly over 
time and carrier (BAFF), while the recovery of eotaxin (Fig 3B) did change significantly over 
time or between the two carriers. Y-axis shows mean cytokine concentration (pg/ml) with 
standard error of mean as error bars and x-axis time (hours). 
Figure 4 – Bar plot of all relative recoveries.
Fig 4 shows the mean relative recoveries (error bars represent standard error of mean) from 
all 3 independent experiments and pooled 24- and 48-hour time points. Y-axis displays the 
cytokines/chemokines while X-axis shows relative recovery.
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Supplementary Table 1. Concentrations of the 39 cytokine and chemokine standards sampled for 
during the in vitro tests. The standards were diluted to concentrations that reflect those found in 
the brain’s extracellular fluid as shown previous experiments from our group,1, 2 assuming a 20% 
relative recovery (RR).3 Additionally, we presented the actual, measured concentrations of the 
external solution at time points 0, 24 and 48 hours. 
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 * Concentration prepared by assuming the weight of each cytokine (micrograms per ampoule) as 
supplied and specified by the manufacturer, and then diluted in an appropriate volume of external 
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